Stephen Hart is Professor in Molecular Genetics at University College London, Institute of Child Health since 2012. He obtained his PhD from the University of Cape Town in 1991 and has since worked in the field of genetic therapies with more than 100 publications in the field.
His research has focused particularly on the development of non-viral, nanoparticle formulations for nucleic acid delivery to the lung based on nanoformulations of epithelial targeting peptides and lipids. Current research activities include the use of these targeted nanocomplexes for the development and delivery of gene, mRNA and siRNA therapies as well as gene editing for primary ciliary dyskinesia and cystic fibrosis.
He has held grants from numerous charities and funding bodies in the UK including the Wellcome Trust, EPSRC and BBSRC, Cystic Fibrosis Trust, Action Medical Research, Sparks and Worldwide Cancer Research. He is the founder scientist of Nanogenic Solutions Ltd, a UCL spin-out company commercialising nanoparticle formulations for gene and siRNA delivery.